67 terminated. 67 Phase 3, 10 Phase 2.
By phase and status
Follow Tauopathies: new trials by email Literature Review of Tauopathies trials Research Report on Tauopathies
Trials (filtered) newest first · largest first
All 67 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study AXS-05 (dextromethorphan-bupropion) - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease Phase 3 Terminated 139 2024-11-21 2026-06-25 Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects Experimental: ALZ-801 - Early Alzheimer's Disease Phase 3 Terminated 163 2024-04-02 2026-06-25 Open-label Extension for Phase 3 Clinical Trials of Simufilam Simufilam - Alzheimer Disease Phase 3 Terminated 1081 2022-11-07 2025-05-23 Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease Piromelatine 20 mg, Placebo - Alzheimer's Disease Phase 2 / Phase 3 Terminated 216 2022-06-15 2026-09-09 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease Aducanumab, Placebo - Alzheimer's Disease Phase 3 Terminated 1027 2022-06-02 2025-04-23 A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) Gantenerumab, Placebo - Alzheimers Disease Phase 3 Terminated 25 2022-04-19 2025-06-12 Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease Simufilam, Placebo - Alzheimer Disease Phase 3 Terminated 1125 2021-11-18 2025-09-22 Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease ATH-1017 - Alzheimer Disease Phase 2 / Phase 3 Terminated 423 2021-06-30 2025-04-01 A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) Gantenerumab - Alzheimer Disease Phase 3 Terminated 1382 2021-01-26 2024-05-08 Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type AVP-786, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type Phase 3 Terminated 241 2020-09-11 2025-05-30 Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type AVP-786, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type Phase 3 Terminated 184 2020-07-13 2025-05-30 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation Gantenerumab - Alzheimers Disease, Dementia Phase 2 / Phase 3 Terminated 73 2020-06-03 2025-02-04 A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD) Gantenerumab - Alzheimer Disease Phase 3 Terminated 116 2020-05-22 2024-01-18 A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 Aducanumab - Alzheimer's Disease Phase 3 Terminated 1696 2020-03-02 2025-02-21 Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Gantenerumab, Placebo - Alzheimer Disease Phase 3 Terminated 975 2018-08-22 2024-01-17 Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD) Gantenerumab, Placebo - Alzheimer Disease Phase 3 Terminated 1053 2018-06-06 2024-01-30 An Open-Label Crenezumab Study in Participants With Alzheimer's Disease Crenezumab - Alzheimer's Disease Phase 3 Terminated 149 2018-04-11 2020-07-13 A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease CNP520 50mg, CNP520 15mg, Matching placebo - Alzheimers Disease Phase 2 / Phase 3 Terminated 1145 2017-08-03 2021-08-05 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Crenezumab, Placebo - Alzheimer's Disease Phase 3 Terminated 806 2017-03-29 2020-07-16 A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia Lanabecestat - Alzheimer's Disease Phase 3 Terminated 421 2017-03-15 2019-12-03
Showing 20 of 67. Sign in to see all of them.
Narrower conditions Alzheimer Disease (65) · Dementia (20) · Central Nervous System Diseases (6) · Mental Disorders (6) · Nervous System Diseases (6) · Brain Diseases (5) · Cognitive Dysfunction (5) · Neurodegenerative Diseases (5) · Neurocognitive Disorders (4) · Psychomotor Agitation (3) · Delirium (2) · Supranuclear Palsy, Progressive (2) · Depressive Disorder (1) · Frontotemporal Dementia (1)
Broader conditions Brain Diseases (62) · Neurodegenerative Diseases (62) · Central Nervous System Diseases (61) · Nervous System Diseases (61) · Neurocognitive Disorders (61) · Mental Disorders (59) · Dementia (45) · Neurologic Manifestations (9) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Neurobehavioral Manifestations (6) · Cognition Disorders (5) · Aberrant Motor Behavior in Dementia (3) · Behavior (3)
Interventions gantenerumab (6) · bapineuzumab (5) · aducanumab (4) · latrepirdine (4) · 7-chloro-N-quinuclidin-3-yl-benzo(b)thiophene-2-carboxamide (3) · crenezumab (3) · lanabecestat (3) · solanezumab (3) · Memantine (2) · Simufilam (2) · Umibecestat (2) · azeliragon (2) · flutemetamol (2) · tarenflurbil (2) · verubecestat (2)
Sponsors Hoffmann-La Roche (8) · Pfizer (7) · Biogen (4) · AstraZeneca (3) · Eli Lilly and Company (3) · FORUM Pharmaceuticals Inc (3) · Merck Sharp & Dohme LLC (3) · Cassava Sciences, Inc. (2) · GlaxoSmithKline (2) · H. Lundbeck A/S (2) · Janssen Research & Development, LLC (2) · Myrexis Inc. (2) · Novartis Pharmaceuticals (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · vTv Therapeutics (2)
Countries United States (52) · Canada (43) · Spain (36) · United Kingdom (36) · Germany (32) · Australia (31) · France (29) · Italy (27) · Poland (26) · South Korea (26) · Japan (24) · Belgium (22) · Netherlands (19) · Sweden (18) · Finland (17)
Top investigators James Kupiec, MD (2) · Mark Laughlin, MD (2) · Aaron H Burstein, PharmD (1) · Amanda G Smith, MD (1) · Ann Gooch, Ph.D. (1) · Christoph Hock, MD, Prof. (1) · Ilise Lombardo, MD (1)
Results publications PMID 40603145 , PMID 39556389 , PMID 41537338 , PMID 42841310 , PMID 26297092 , PMID 27176461 , PMID 27334799 , PMID 27767991 , PMID 27807285 , PMID 31764959 , PMID 33049114 , PMID 34807243 , PMID 35384522 , PMID 36121669 , PMID 36600109 , PMID 36641609 , PMID 37966285 , PMID 38165296 , PMID 39498781 , PMID 39887500 , PMID 40302041 , PMID 42598748 , PMID 19029129 , PMID 19771175 , PMID 21386111 , PMID 21829612 , PMID 23472619 , PMID 24591834 , PMID 27846868 , PMID 29365294 , PMID 29719179 , PMID 30970186 , PMID 31387606 , PMID 33252075 , PMID 33253354 , PMID 33464300 , PMID 35794343 , PMID 35897078 , PMID 36744336 , PMID 36946603 , PMID 38087949 , PMID 38599894 , PMID 38940656 , PMID 39559869 , PMID 39974075 , PMID 40120616 , PMID 40375477 , PMID 40413110 , PMID 40545559 , PMID 41085131
NIH funding 2015 (6) , 2016 (5) , 2017 (3) , 2023 (2) , 1UF1AG046150-01 (1) , 2008 (1) , 2009 (1) , 2014 (1) , 2019 (1) , R01AG046179 (1) , R01AG053267 (1) , R56AG053267 (1) , U01AG042791 (1) , U01AG059798 (1)